171 related articles for article (PubMed ID: 24033561)
1. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades.
Lazar L; Meyerovitch J; de Vries L; Phillip M; Lebenthal Y
Clin Endocrinol (Oxf); 2014 Apr; 80(4):570-6. PubMed ID: 24033561
[TBL] [Abstract][Full Text] [Related]
2. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades.
Lazar L; Lebenthal Y; Yackobovitch-Gavan M; Shalitin S; de Vries L; Phillip M; Meyerovitch J
J Clin Endocrinol Metab; 2015 Apr; 100(4):1445-51. PubMed ID: 25650898
[TBL] [Abstract][Full Text] [Related]
3. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
4. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function.
Heger S; Müller M; Ranke M; Schwarz HP; Waldhauser F; Partsch CJ; Sippell WG
Mol Cell Endocrinol; 2006 Jul; 254-255():217-20. PubMed ID: 16757104
[TBL] [Abstract][Full Text] [Related]
5. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
Bertelloni S; Mucaria C; Baroncelli GI; Peroni D
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):659-667. PubMed ID: 29957076
[TBL] [Abstract][Full Text] [Related]
6. Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study.
Martinerie L; de Mouzon J; Blumberg J; di Nicola L; Maisonobe P; Carel JC;
Horm Res Paediatr; 2020; 93(9-10):529-538. PubMed ID: 33774631
[TBL] [Abstract][Full Text] [Related]
7. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment.
Sørensen K; Andersson AM; Skakkebaek NE; Juul A
J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314
[TBL] [Abstract][Full Text] [Related]
8. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
9. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method.
Kauli R; Galatzer A; Kornreich L; Lazar L; Pertzelan A; Laron Z
Horm Res; 1997; 47(2):54-61. PubMed ID: 9030968
[TBL] [Abstract][Full Text] [Related]
10. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.
Guaraldi F; Beccuti G; Gori D; Ghizzoni L
Eur J Endocrinol; 2016 Mar; 174(3):R79-87. PubMed ID: 26466612
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height.
Lazar L; Kauli R; Pertzelan A; Phillip M
J Clin Endocrinol Metab; 2002 May; 87(5):2090-4. PubMed ID: 11994346
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
Magiakou MA; Manousaki D; Papadaki M; Hadjidakis D; Levidou G; Vakaki M; Papaefstathiou A; Lalioti N; Kanaka-Gantenbein C; Piaditis G; Chrousos GP; Dacou-Voutetakis C
J Clin Endocrinol Metab; 2010 Jan; 95(1):109-17. PubMed ID: 19897682
[TBL] [Abstract][Full Text] [Related]
13. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
14. Serum inhibin A and inhibin B in central precocious puberty before and during treatment with GnRH agonists.
Sehested A; Andersson AM; Müller J; Skakkebaek NE
Horm Res; 2000; 54(2):84-91. PubMed ID: 11251372
[TBL] [Abstract][Full Text] [Related]
15. Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment: a pilot study.
Menk TAS; Inácio M; Macedo DB; Bessa DS; Latronico AC; Mendonca BB; Brito VN
J Pediatr Endocrinol Metab; 2017 May; 30(6):657-662. PubMed ID: 28599388
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate.
Hertel NT; Stoltenberg M; Juul A; Main KM; Müller J; Nielsen CT; Lorenzen I; Skakkebaek NE
J Clin Endocrinol Metab; 1993 Apr; 76(4):924-7. PubMed ID: 8473407
[TBL] [Abstract][Full Text] [Related]
17. Menstrual cycle, reproductive function, body mass index, and metabolic profiles of women with former central precocious puberty: 10-20-year longitudinal cohort study in southern Thailand.
Satitpatanapan P; Jaruratanasirikul S; Sriplung H
J Pediatr Endocrinol Metab; 2020 Jul; 33(7):933-940. PubMed ID: 32623380
[TBL] [Abstract][Full Text] [Related]
18. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
[TBL] [Abstract][Full Text] [Related]
19. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty.
Kanety H; Karasik A; Pariente C; Kauschansky A
Clin Endocrinol (Oxf); 1996 Jul; 45(1):7-12. PubMed ID: 8796132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
